The immune system provides defense against tumors and pathogens. Here, we propose that by elucidating the shared principles of immunity that underlie cancer and infectious disease, oncologists and microbiologists can learn from each other and achieve the deeper mechanistic understanding critical the development of therapeutic approaches.
INTRODUCTION
From their earliest days, the fields of microbio logy and immunology have been inextricably linked. Collaborations between microbiolo gists, immunologists, and infectious disease specialists led to vaccines that have saved millions of lives by virtually or entirely elim inating many of humankind's major scourges, including diphtheria, polio, and smallpox. Although certain infectious diseases have resisted vaccine development, suc h as malaria, tuberculosis (TB), and AIDS, vaccines re main among the most effective measures to combat infectious disease.
In contrast to infectious diseases, which have been severely curtailed in the developed world, cancer remains a major cause of mor bidity in both the developed and developing world. Unlike microbiology and immunology, the fields of infectious diseases and cancer have not been extensively linked, although there are a few exceptions. For example, up to 20% of cancers are caused by infectious agents, including Helicobacter pylori, Kaposi's sarcomaassociated herpesvirus (KSHV), hep atitis C virus, and Rous sarcoma virus (RSV) (1) . Indeed, stu dies of RSV were instrumental to the discovery of oncogenes (2) . Although the importance of the immune system in com bating infectious disease is indisputable, for many years there was controversy on the role of the immune system in naturally combating cancer and on whether it would be possible to exploit the immune system to treat cancer. With the recent successes of cancer immuno therapy, however, it is clear that therapeutic and prophylactic manipulations of the im mune system are key approaches to treating and/or preventing both infectious diseases and cancer.
Here, we ask how the study of infectious diseases has and may continue to influence cancer immunotherapy, and likewise, we ask how the success of cancer immunotherapy might reciprocally lead to approaches with which to attack infectious diseases that have remained intractable to vaccine develop ment (Fig. 1) .
Do similar immunological principles apply to infections and tumors?
Our understanding of the immune response has largely been derived from studies of in fections and model antigens. It is therefore reasonable to ask to what extent this under standing applies to the immune response to tumors. The diversity of both infectious agents and cancers makes generalizations difficult. Indeed, the principles of immunity derived from one infectious agent do not necessarily apply even to another infectious agent, let alone a tumor. Nevertheless, we propose that there exist shared immunological mechanisms that underlie infectious diseases and cancer pathologies, and thus, crossfertilization of ideas between these fields has been and will likely continue to be fruitful.
One important principle of immunity is that immune responses are usually initiated upon detection of conserved microbespecific molecules called pathogenassociated molec ular patterns (PAMPs) that are recognized by germlineencoded pattern recognition re ceptors (PRRs) (3) . PAMPs are expected to be absent from tumors, which are (with a few exceptions mentioned below) selfderived, implying that the PAMP concept might not have relevance to cancer immunology. How ever, not all PAMPs are microbespecific. For example, double stranded DNA (dsDNA), found in all cells, is a PAMP that is recognized by at least three distinct PRRs (TLR9, AIM2, and cGAS). The ability of the innate immune system to distinguish self from foreign dsDNA relies on detecting dsDNA of different origins in distinct subcellular compartments (4). Self dsDNA is generally nuclear, whereas TLR9 recognizes (foreign) dsDNA in endosomes, and AIM2 and cGAS recognize cytosolic dsDNA. It is plausible that the cell death and genomic instability that occur in tumors might lead to aberrant localization of DNA. Indeed, there is growing evidence that the cGAS mediated dsDNA detection pathway plays a role in initiation of immune responses to tumors [(5); discussed below]. In addition, despite the centrality of PAMPs to innate immunity, it has long been appreciated that nonPAMP based mechanisms can also initiate immune responses. These mechanisms are diverse but are unified by the common idea that disrup tions of normal cellular physiology can be detected by the immune system (6) (7) (8) . For example, natural killer (NK) cells recognize cells that have aberrantly downregulated ex pression of MHC class I (9), a characteristic often exhibited by both transformed and viral ly infected cells. The DNA damage response, often activated in transformed cells and pre cancerous lesions, is also now appreciated to stimulate a diverse set of immune responses (10) . Thus, it is likely that diverse innate im mune mechanisms that evolved primarily to defend against infections might also have utility in detecting tumors.
Another hallmark of immunity is self/non self discrimination, a principle that is most clearly exemplified by the specific recognition of pathogenencoded epitopes by the antigen receptors of B and T lymphocytes. It is not im mediately obvious that this central concept would apply to tumors, because again, tumors are es sentially "self" cells. Indeed, although immune responses can be raised against arbitrary non natural chemical structures, it is generally un derstood that the immune system evolved in large part to recognize "nonself" in the form of pathogenic microbes. However, numerous recent cancer exome sequencing projects have revealed that tumors can carry a large spec trum of mutated proteins that can be detected as nonself (11) . In addition, there is evi dence that unmutated self proteins can also be the subject of "autoimmune" recognition in the context of cancer (12) .
Self/nonself discrimination is not the only immunological concept with relevance to both infectious disease and cancer: Phago cytosis, cell death, cellcell communication, cell migration, cell extravasation, development of immune microenvironments, and immune evasion and suppression are all immunologi cal processes with direct relevance to cancer (13) . However, the most prominent immunologi cal process relevant to infections and tumors is almost certainly inflammation, a complex constellation of physiological states that aris es during immune responses. Inflammation, as is often pointed out, is a double edged sword, with obvious benefits but also important nega tive consequences for the host. During acute infections, inflammation is critical to recruit anti microbial immune cells to the site of in fection. This results in tissue destruction, but ideally, the damage is loc alized. Systemic effects of inflammation, such as fever, are also ideally transient. In deed, a key component of the inflammatory cascade is the initia tion of pro resolution tissue repair and heal ing responses (14) . Thus, when it func tions well during an acute response, inflam mation can elim inate infections and tumors and restore homeo stasis. Problems arise when inflammation does not resolve appro priately or is inappro priately regulated; this scenario is re levant to both chronic infec tions and cancer. It is now wellappreciated that chronic inflam mation is an import ant cause of cellular damage, enhanced cel lular proliferation, angiogenesis, and immu nosuppression that can promote tumorigenesis (1, 13) . Indeed, the chronic inflammation as sociated with certain persistent infections, for example, those caused by H. pylori or hu man papilloma virus (HPV), is believed to be an important cause of the gastric and cer vical cancers associated with these agents. In addition to causing cancer, inflammation also appears to contribute to the morbidity and mortality of cancer. The multiorgan dys function and sys temic metabolic pathology, such as cachexia (wasting), which ultimately underlie many cancer deaths, likely arise at least in part due to chronic inflammation (15) . Interestingly, similar physiological effects are observed in chronic infectious diseases such as AIDS or TB. Indeed, an interesting way to think of cancer is as a chronic infectious disease-the consequence of the unresolved presence and growth of a "foreign" body. For example, many concepts relevant to the treat ment of chronic infections, including multidrug resistance, are also relevant to the treatment of tumors. The close conceptual similarity between chronic infections and cancers is underlined most dramatically by several exam ples of cancers that are literally infectious agents, for example, the transmissible tumors of Tasmanian devils (16) and bivalves (17) . (18) . Animal studies suggest that BCG injections mobilize CD4 and CD8 T cells as well as NK cells against tumors (19) .
How have studies of infection led to cancer immunotherapies?
Checkpoint immunotherapies also owe a major debt to infection studies. Although the concept of CTLA4 blockade arose from studies of T cell costimulation (20) , the role of PD1 in T cell exhaustion emerged most directly in studies of T cell dysfunction in chronic viral infections in mice (21) . Evidence emerged from those studies that blockade of the PD1 interaction with its ligand PDL1 restored the activity of exhausted CD8 T cells and reduced viral loads, vitalizing efforts to apply PD1 blockade for immunotherapy of cancer.
Chimeric antigen receptor (CAR) therapy, which has proven successful against hemato logical malignancies, was first conceived in a proofofprinciple format, with a test antigen, trinitrophenyl, as a target (22) . However, the first attempt to engineer diseasespecific T cells involved targeting HIVinfected cells and not cancer (23) . In fact, targeting pathogen infec tions with CAR T cells remains a very active field of research (24) .
An obvious area of overlap of infectious disease and cancer immunology is in the de sign and application of vaccines. Most vaccines for infectious disease agents are prophylactic (for example, healthy people are vaccinated to prevent infections), whereas most efforts in cancer immunology are therapeutic (patients are treated after diagnosis). To date, prophylactic vaccines to prevent cancer are limited to in stances where tumors are caused by pathogens, and the vaccine targets the pathogen. Im portant examples are the HPV and hepatitis B virus vaccines, which strongly reduce the risk of cervical cancer and hepatocellular carcinoma, respectively (25, 26) . Prophylactic vaccines against cancers that are not pathogen induced remain an ambitious goal (27) . 
Fig. 1. Shared immunological principles, responses, and potential therapies for infectious disease and cancer.
Although cancers and infections exhibit considerable diversity and encompass many unique aspects, the figure emphasizes how shared immunological principles, responses, and therapies potentially play important roles in both types of disease.
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On the other hand, therapeutic vaccination for cancer is an area of intense investigation (28) . Therapeutic vaccination is unlikely to be effective for most acute infections due to the rapidity of pathogen growth but has been ap plied for rabies and may be a valuable future approach for other chronic or slowly develop ing infections (29) . The basis of most, if not all, successful infectious disease vaccines is the induction of antibodies that effectively neutralize mi crobes or their toxins. Indeed, the first Nobel Prize was awarded to Emil von Behring for his discovery that diphtheria antitoxin prevented disease. Since the emergence of antibiotics and vaccines, passive serotherapy is no longer commonly applied in infectious disease. In contrast, antitumor monoclonal (for example, rituximab) and bispecific (such as catumaxomab) anti bodies are used clinically for cancer with variable success (30) . However, many current immunotherapy approaches seek to stimu late another arm of the immune system, cell mediated immunity, which involves cytolytic lymphocytes that are able to recognize and kill tumor cells. Cancer vaccines have typically used tumor antigens mixed with antigen presenting cells and adjuvant costimuli to amplify the immunogenicity of the antigen presenting cells. Such cancer vaccines, for ex ample Provenge, have so far been modestly successful. Vaccines targeting T cell responses may be limited in potency because the antigen presenting cells are not adequately activated and are therefore not sufficiently immuno stimulatory. Platforms to drive stronger CD8 T cell responses are therefore of great inter est. Interestingly, many of the important in fectious diseases for which we have failed to develop protective vaccines (such as, AIDS, TB, and malaria) are caused by intracellular pathogens (31) , and successful immune re sponses to intracellular pathogens also gen erally involve cellmediated immunity. Thus, strategies to enhance cellmediated immu nity are likely of interest to the fields of both immuno oncology and infectious disease. New types of attenuated vaccine platforms have been developed based on the understand ing of the infectious life cycle of intracellular pathogens such as Listeria monocytogenes (32) or viruses of various categories (33) . These vaccines deliver antigens to the cytoplasm of infected cells and provide adjuvant effects as well as sustained availability of the target anti gen and antigens for T cell help, all conducive to generating strong CD8 T cell responses. Such vaccine strains may be especially useful for emerging cancer vaccines that are based on the postdiagnosis identification of "neo antigens" specific to a patient's tumor (11) , fol lowed by generation and application of vac cines to amplify tumorspecific T cells against those antigens.
Therapeutic targeting of PRRs represents another very important bridge from infection studies to cancer therapies. PAMPs that en gage Tolllike receptors (TLR), including CpG and poly(I:C) (doublestranded RNA), have been tested in clinical trials (34) , and one such drug that activates TLR7, imiquimod, is approved for treating superficial basal cell car cinomas (35) . Combining such ligands with vaccines or conventional therapies is also be ing extensively investigated.
A new PRRbased approach with great pro mise for cancer immunotherapy has emer ged from the findings that bacteria se crete immunestimulating cyclic dinucleotides (CDNs), consisting of cyclized dimers of gua nosine and/or adenosine nucleotides. Bac terial CDNs are potent inducers of type I interferon (IFN) responses by immune cells (36) (37) (38) . A key finding was that CDNs bind and activate the endoplasmic reticulum-membrane resi dent signaling protein STING (39) , which is also essential for the IFN response of cells that accumulate intracytoplasmic DNA (40) . Mammalian cells con tain a cytoplasmic enzyme, cGAS, which is activated by cytoplasmic DNA to synthesize a specific CDN isoform called cGAMP (41) . The STINGcGAS pathway is now known to be necessary for protective re sponses against certain viruses (42) . A role for this pathway in immuneoncology emerged when it was found that the STING pathway is essential for strong antitumor immune responses against transferred tumors (43) . With respect to therapy, CDNs, injected di rectly into tumors, stimulate potent immune mediated antitumor responses, expansions of cytotoxic T cells, and tumor regressions (43) . Activity against distant metastases was also observed. Based on these promising find ings, CDNs are now entering clinical trials in multiple types of cancer.
How might the success of cancer immunotherapy be applied to infectious disease?
The success of cancer immunotherapy is lead ing to new insights and renewed efforts to en hance and modulate the immune system's activity toward infectious diseases. For exam ple, "checkpoint" therapies that block inhibi tory immunoreceptors are being advanced in chronic infections to overcome T cell ex haustion. PD1 blockade in the SIV macaque model demonstrated rapid expansion of virus specific CD8 T cells with improved func tional quality, leading to reduced viral loads and prolonged survival (44) . Blocking of PD1 in a chimpanzee HCV model similarly showed Table 1 . Questions for further thought. There are still numerous outstanding questions to be addressed to better understand the similarities and differences between immune responses to infections and tumors. • In what respects is the immune response to a tumor similar to the immune response to a chronic infection?
• Why are therapeutic vaccines rarely used to treat infections? Given this, why is it believed that they may be useful in treating cancer?
• Can prophylactic vaccines be developed for cancer?
• Could passive monoclonal or bispecific antibody therapies used to treat cancer also be applied to infections?
• Can checkpoint blockade provide an effective therapeutic strategy for infections?
• How can cytotoxic T cell responses best be elicited in a vaccine? Would such vaccines be of benefit for immunization against tumors and intracellular pathogens for which we currently lack effective vaccines?
an ability to restore antiviral CD4 and CD8 T cell responses and control of viral replica tion (45) . The importance of PD1 as well as other coinhibitory receptors, such as CTLA 4, TIM3, and LAG3, has been confirmed in multiple viral, bacterial, and parasitic infec tions (46) , suggesting broader application of this approach to managing infections. The emphasis on innate immune stimula tion, generating cytotoxic T cell responses, and identifying effective T cell antigens for cancer immunotherapies are destined, in turn, to give infectious disease vaccinology a boost. Computational and "omics" approaches to identify and validate immunostimulatory antigens and epitopes are critical for both cancer and infectious disease vaccine design (47, 48) . Applications of these approaches to infectious disease challenges, such as creating a universal vaccine for influenza, have shown promising results (49) . Adjuvants that pro mote cellular immunity will be essential for targeting intracellular pathogens and viral in fections. Studies applying STING pathway agonists as adjuvants or therapies in a variety of infections are underway (50) . Vector sys tems that selectively elicit strong CD8 T cell responses such as L. monocytogenes, as well as poxviruses and adenoviruses, are seeing ap plication in infections such as HIV, hepatitis C, TB, malaria, and leishmaniasis (51) . Exciting approaches to enhancing NK cell responses, which target both cancers and infectious dis eases, are emerging (52) . As with vaccine tech nology, advances in CAR T cell therapy for hematological malignancies may lead to ap plications in infectious diseases. Methods for receptor design and delivery have advanced rapidly (53) and are being reapplied to CAR T cell therapies for HIV and other chronic infections (24) .
CONCLUSION: FUTURE OPPORTUNITIES
Despite many notable therapeutic successes, infectious diseases and cancer remain as major causes of global morbidity and mortality. A better understanding of how the immune system successfully responds to pathogens may lead to the design and implementation of strat egies to elicit similar responses to tumors. Conversely, therapeutic approaches proven to work in the context of cancer may have application to infectious diseases, particu larly chronic infections and/or those caused by intracellular pathogens. Thus, we suspect that immunooncologists and infectious disease immunologists still have a lot to learn from each other ( Table 1) .
